Publications by authors named "Everardo D Saad"

Claim this Profile
C
Clinical trials for older cancer patients: A systematic review.
Roberta Fazio, Alessandro Audisio, Giacomo Bregni, Daniel Sur, Valentina Daprà, Everardo D Saad

Cancer Treat Rev· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clarifying End Point Definitions, Missingness, and Covariate Balance in the International TNT Study-Reply.
Francesco Sclafani, Vincent Staggs, Everardo D Saad

JAMA Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.
Alessandro Audisio, Chiara Gallio, Vaneja Velenik, Hélène Meillat, Erika Ruiz-Garcia, Everardo D Saad

JAMA Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Noninferiority trials in oncology: need for improvement, or a paradigm shift?
Marc Buyse, Everardo D Saad

J Natl Cancer Inst· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generalized Pairwise Comparisons to Support Shared Decision-Making in the CODA Trial.
Samuel Salvaggio, Sarah E Monsell, Patrick J Heagerty, Mickael De Backer, Emilie Barré, Everardo D Saad

JAMA Netw Open· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of a clinical trial using generalized pairwise comparisons to test a less intensive treatment regimen.
Mickaël De Backer, Manju Sengar, Vikram Mathews, Samuel Salvaggio, Vaiva Deltuvaite-Thomas, Everardo D Saad

Clin Trials· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rethinking survival analysis: advancing beyond the hazard ratio?
Johan Verbeeck, Everardo D Saad

Eur Heart J Acute Cardiovasc Care· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimization in randomized clinical trials.
Elisabeth Coart, Perrine Bamps, Emmanuel Quinaux, Geneviève Sturbois, Everardo D Saad

Stat Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trial Design for Cancer Immunotherapy: A Methodological Toolkit.
Everardo D Saad, Elisabeth Coart, Vaiva Deltuvaite-Thomas, Leandro Garcia-Barrado, Tomasz Burzykowski

Cancers (Basel)· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy.
Pierre Squifflet, Everardo D Saad, Sibylle Loibl, Marion T van Mackelenbergh, Michael Untch

J Clin Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
Marion T van Mackelenbergh, Sibylle Loibl, Michael Untch, Marc Buyse, Charles E Geyer, Everardo D Saad

J Clin Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The case against censoring of progression-free survival in cancer clinical trials - A pandemic shutdown as an illustration.
Corinne Jamoul, Laurence Collette, Elisabeth Coart, Koenraad D'Hollander, Tomasz Burzykowski, Everardo D Saad

BMC Med Res Methodol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology.
Richard M Goldberg, Richard Adams, Marc Buyse, Cathy Eng, Axel Grothey, Everardo D Saad

J Natl Cancer Inst· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surrogacy Beyond Prognosis: The Importance of "Trial-Level" Surrogacy.
Marc Buyse, Everardo D Saad, Tomasz Burzykowski, Meredith M Regan, Christopher S Sweeney

Oncologist· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient Eligibility and Results for Brain Metastasis in Phase 3 Trials of Advanced Breast Cancer: A Scoping Review.
Renata Duchnowska, Everardo D Saad, Małgorzata Banaszek, Ewa Pawłowska, Hanna Liberek

Cancers (Basel)· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Net Benefit of a treatment should take the correlation between benefits and harms into account.
Marc Buyse, Everardo D Saad, Julien Peron, Jean-Christophe Chiem, Mickaël De Backer

J Clin Epidemiol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brazilian Validation of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group (QLG) Computerised Adaptive Tests (CAT) Core.
Gustavo Nader Marta, Tomás Y T de Souza, Alice R N de Souza E Silva, Ana Paula A Pereira, David R Ferreira Neto, Everardo D Saad

Curr Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers at a tertiary centre with a multi-gene, tumor-agnostic, next generation sequencing panel.
Giacomo Bregni, Tiberio Sticca, Silvia Camera, Tugba Akin Telli, Ligia Craciun, Everardo Delforge Saad

Acta Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statistical Considerations for Trials in Adjuvant Treatment of Colorectal Cancer.
Everardo Delforge Saad, Marc Buyse

Cancers (Basel)· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Commentary on Bamat et al.
Everardo D Saad, Marc Buyse

Clin Trials· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors.
Elisabeth Coart, Stefan Suciu, Pierre Squifflet, Everardo D Saad, Andriy Moshyk

Eur J Cancer· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statistical aspects in adjuvant and neoadjuvant trials for gastrointestinal cancer in 2020: focus on time-to-event endpoints.
Everardo D Saad, Marc Buyse

Curr Opin Oncol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Central statistical monitoring of investigator-led clinical trials in oncology.
Marc Buyse, Laura Trotta, Everardo D Saad, Junichi Sakamoto

Int J Clin Oncol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronological Trends in Progression-Free, Overall, and Post-Progression Survival in First-Line Therapy for Advanced NSCLC.
Jacek Rutkowski, Everardo D Saad, Tomasz Burzykowski, Marc Buyse, Jacek Jassem

J Thorac Oncol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer.
Tomasz Burzykowski, Elisabeth Coart, Everardo D Saad, Qian Shi, Dirkje W Sommeijer

JAMA Netw Open· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis